NexgenRX Inc (NXG.V)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of CA$10,000 in NexgenRX Inc, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

NexgenRX Inc (NXG.V) has returned -17.50% so far this year and 23.26% over the past 12 months. Over the last ten years, NXG.V has returned 9.14% per year, falling short of the S&P 500 Index benchmark, which averaged 12.91% annually.

Based on dividend-adjusted daily data since Sep 14, 2006, NXG.V's average daily return is +0.14%, while the average monthly return is +0.70%. At this rate, your investment would double in approximately 8.3 years.

Historically, 42% of months were positive and 58% were negative. The best month was Sep 2007 with a return of +36.0%, while the worst month was Aug 2014 at -25.0%. The longest winning streak lasted 6 consecutive months, and the longest losing streak was 6 months.

On a daily basis, NXG.V closed higher 11% of trading days. The best single day was Dec 9, 2008 with a return of +72.7%, while the worst single day was Nov 6, 2008 at -52.4%.

NexgenRX Inc has an annualized alpha of 34.82%, beta of 0.17, and R² of 0.00 versus S&P 500 Index. Calculated based on daily prices since September 15, 2006.

• This stock participated in 62.96% of S&P 500 Index downside but only 26.48% of its upside — more exposed to losses than it benefited from rallies.
• Beta of 0.17 may look defensive, but with R² of 0.00 this stock is largely uncorrelated with S&P 500 Index — low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
• R² of 0.00 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

NXG.V ranks 63 for risk / return — better than 63% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.

The table below present risk-adjusted performance metrics for NexgenRX Inc (NXG.V) and compare them to a chosen benchmark (S&P 500 Index).

NexgenRX Inc provided a 4.55% dividend yield over the last twelve months, with an annual payout of CA$0.02 per share. The company has been increasing its dividends for 3 consecutive years.

The table displays the monthly dividend distributions for NexgenRX Inc. The dividends shown in the table have been adjusted to account for any splits that may have occurred.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the NexgenRX Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the NexgenRX Inc was 85.45%, occurring on Jan 16, 2015. The portfolio has not yet recovered.

The current NexgenRX Inc drawdown is 30.22%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of NexgenRX Inc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how NexgenRX Inc is priced in the market compared to other companies in the Health Information Services industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.